ValuEngine cut shares of ViewRay (NASDAQ:VRAY) from a hold rating to a sell rating in a report published on Friday morning.

Several other research firms have also commented on VRAY. Mizuho restated a buy rating and set a $12.00 price target on shares of ViewRay in a research report on Wednesday, October 25th. Northland Securities reiterated a buy rating and issued a $10.00 target price on shares of ViewRay in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. ViewRay has an average rating of Buy and a consensus target price of $10.60.

ViewRay (NASDAQ:VRAY) traded up $0.27 during trading on Friday, hitting $9.90. 1,800,000 shares of the stock traded hands, compared to its average volume of 1,030,000. The company has a debt-to-equity ratio of -1.67, a current ratio of 1.59 and a quick ratio of 1.20. ViewRay has a fifty-two week low of $3.01 and a fifty-two week high of $10.39.

ViewRay (NASDAQ:VRAY) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. ViewRay’s revenue for the quarter was up 2950.0% on a year-over-year basis. equities research analysts predict that ViewRay will post -0.91 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pura Vida Investments LLC grew its position in ViewRay by 132.9% in the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after buying an additional 346,370 shares in the last quarter. Fosun International Ltd bought a new position in ViewRay in the 3rd quarter valued at about $640,000. RTW Investments LP grew its position in ViewRay by 33.5% in the 3rd quarter. RTW Investments LP now owns 1,020,462 shares of the company’s stock valued at $5,878,000 after buying an additional 256,127 shares in the last quarter. Wells Fargo & Company MN grew its position in ViewRay by 95.9% in the 3rd quarter. Wells Fargo & Company MN now owns 37,802 shares of the company’s stock valued at $218,000 after buying an additional 18,502 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in ViewRay in the 3rd quarter valued at about $174,000. Hedge funds and other institutional investors own 50.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/02/viewray-vray-downgraded-to-sell-at-valuengine.html.

About ViewRay

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Analyst Recommendations for ViewRay (NASDAQ:VRAY)

Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.